September 9, 2026 · 2 min read

TB-500 and thymosin beta-4: separating the parent protein from the marketed fragment

Thymosin beta-4 has decades of published work. TB-500, sold as a fragment of it, has very little. A research overview of where each stands.

Most of what gets said online about TB-500 is really about thymosin beta-4 (Tβ4), the 43-amino-acid protein it is marketed as a fragment of. Those are not the same molecule, and the evidence for them is very different in size. This piece keeps them apart.

Thymosin beta-4: the parent protein

Sequence: Serine, Aspartic acid, Lysine, Proline, Aspartic acid, Methionine, Alanine, Glutamic acid, Isoleucine, Glutamic acid, Lysine, Phenylalanine, Aspartic acid, Lysine, Serine, Lysine, Leucine, Lysine, Lysine, Threonine, Glutamic acid, Threonine, Glutamine, Glutamic acid, Lysine, Asparagine, Proline, Leucine, Proline, Serine, Lysine, Glutamic acid, Threonine, Isoleucine, Glutamic acid, Glutamine, Glutamic acid, Lysine, Glutamine, Alanine, Glycine, Glutamic acid, Serine.

  • Polar
  • Negatively charged
  • Positively charged
  • Glycine or proline
  • Hydrophobic
Length
43 amino acids
Calculated mass (unmodified)
4,921.5 Da
Human thymosin beta-4 (UniProt P62328), 43 residues after the initiator methionine. The mass is calculated from the sequence and does not include any modification. TB-500 is marketed as a fragment of this protein, and we did not find a sequence for it in the sources cited here.

What thymosin beta-4 does in cells

Hannappel's 2007 review traces how Tβ4 went from a presumed thymic hormone to an actin-sequestering peptide and then to a cytokine-like molecule supporting wound healing. It binds G-actin with a dissociation constant in the micromolar range, which allows quick binding and release. The same review is blunt that very little is known about the molecular mechanisms behind the effects attributed to extracellular beta-thymosins.

How the picture of thymosin beta-4 changed

  1. 1

    Thymic extract

    Isolated from thymosin fraction 5 and first thought to be a thymic hormone.

  2. 2

    Not a true hormone

    None of the isolated peptides turned out to be a real thymic hormone.

  3. 3

    Actin binding

    In 1990 it was shown to sequester G-actin, its main intracellular role.

  4. 4

    Extracellular effects

    Wound-healing effects were attributed to it, but the mechanisms remain poorly understood.

From the review by Hannappel, Ann N Y Acad Sci 2007. A simplified timeline of how the understanding of the protein developed.

Heart and eye work

The strongest preclinical story is in the heart. A 2023 review summarizes the authors' experiments in which Tβ4 was expressed in the developing mouse heart and promoted cardiac cell migration and survival, and, injected after coronary artery ligation in adult animals, improved myocyte survival and cardiac function. It also altered the epicardium toward an embryonic-like state and activated epicardial progenitors. A 2020 review covers Tβ4 in heart injury, and a 2018 review follows its path from bench to bedside in the eye.

Where TB-500 fits

A 2026 review in Sports Medicine lists TB-500 as a thymosin beta-4 fragment among the unapproved compounds sold direct to consumers, and concludes that rigorous human safety data for these peptides are scarce. That fits what we see. When a source says TB-500 does something, check whether the experiment used full-length Tβ4, and check which species it used.

Evidence by compound

  1. Thymosin beta-4

    Decades of cell and animal work, plus clinical development, notably in the eye.

  2. TB-500

    Marketed as a Tβ4 fragment. We found little published work on TB-500 itself.

  3. Human safety

    Rigorous data on unapproved peptides is scarce, per the 2026 sports medicine review.

Our reading of the sources listed below, including the 2026 review by Mendias and Awan. Not a systematic review.

References

  1. Hannappel E. beta-Thymosins. Ann N Y Acad Sci 2007.
  2. Bock-Marquette I et al. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. Int Immunopharmacol 2023.
  3. Bjorklund G et al. Thymosin beta4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. Curr Med Chem 2020.
  4. Sosne G et al. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther 2018.
  5. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026.

Related research notes